Literature DB >> 64473

A soluble acidic protein of the cell nucleus which reacts with serum from patients with systemic lupus erythermatosus and Sjögren's syndrome.

M Akizuki, R Powers, H R Holman.   

Abstract

A soluble nuclear antigen that reacts with sera obtained from patients with systemic lupus erythematosus and Sjögren's syndrome has been described. The antigen, tentatively named the Ha antigen after the prototype serum, was shown to react with specific antibodies by precipitin, complement fixation, and immunofluorescence techniques. The Ha antigen prepared from isolated nuclei of calf thymus glands, calf liver, and rat liver showed identical immunological reactivities; a wide distribution among different species and tissues is presumed. The Ha antigen was destroyed by trypsin and relatively mild heat or pH variation from neutrality, but was resistant to DNase or RNase. Many of these characteristics are similar to those of the "B" antigen to which antibodies have recently been described in Sjögren's syndrome. The nuclear origin of the Ha antigen was confirmed by the speckled nuclear immunofluorescence staining pattern given by purified antibody to Ha obtained from a specific immune precipitate. Preliminary results showed approximately 13% of patients with systemic lupus erythematosus and 30% of patients with Sjögren's syndrome had precipitating antibodies to the Ha antigen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 64473      PMCID: PMC333356          DOI: 10.1172/JCI108637

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  The L. E. cell and the L. E. serum factors.

Authors:  H R HOLMAN; H R DEICHER; H G KUNKEL
Journal:  Bull N Y Acad Med       Date:  1959-07

3.  Complement fixation reactions with DNA and leukocyte material in systemic lupus erythematosus: correlation with the L. E. cell phenomenon and the clinical status.

Authors:  C M PEARSON; C G CRADDOCK; N S SIMMONS
Journal:  J Lab Clin Med       Date:  1958-10

4.  Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein.

Authors:  H R HOLMAN; H G KUNKEL
Journal:  Science       Date:  1957-07-26       Impact factor: 47.728

5.  [Demonstration in the blood of patients with disseminated lupus erythematosus a substance determining a precipitation reaction with desoxyribonucleic acid].

Authors:  M SELIGMANN
Journal:  C R Hebd Seances Acad Sci       Date:  1957-07-08

6.  A DNA-reacting factor in serum of a patient with lupus erythematosus diffusus.

Authors:  R CEPPELLINI; E POLLI; F CELADA
Journal:  Proc Soc Exp Biol Med       Date:  1957-12

7.  Complement fixation with cell nuclei and DNA in lupus erythematosus.

Authors:  W C ROBBINS; H R HOLMAN; H DEICHER; H G KUNKEL
Journal:  Proc Soc Exp Biol Med       Date:  1957-12

8.  [A micro-method of immuno-electrophoresis].

Authors:  J J SCHEIDEGGER
Journal:  Int Arch Allergy Appl Immunol       Date:  1955

9.  Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; N Talal; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

10.  Antibodies to cellular antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; E M Tan
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

View more
  30 in total

Review 1.  Anti-Ro (SSA)/La (SSB) antibodies and Sjögren's syndrome.

Authors:  H M Moutsopoulos; L V Zerva
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 2.  Significance of the Ro antigen system.

Authors:  M Reichlin
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

Review 3.  Antinucleic acid antibodies.

Authors:  E J Holborow
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

4.  Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.

Authors:  H H Guldner; C Szostecki; H P Vosberg; H J Lakomek; E Penner; F A Bautz
Journal:  Chromosoma       Date:  1986       Impact factor: 4.316

Review 5.  Duct-associated lymphoid tissue (DALT) of minor salivary glands and mucosal immunity.

Authors:  P N Nair; H E Schroeder
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

6.  Scl-86, a marker antigen for diffuse scleroderma.

Authors:  W J van Venrooij; S O Stapel; H Houben; W J Habets; C G Kallenberg; E Penner; L B van de Putte
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

7.  Clinical significance of antibodies to soluble extractable nuclear antigens (anti-ENA).

Authors:  A Gaudreau; B Amor; M F Kahn; A Ryckewaert; J Sany; A P Peltier
Journal:  Ann Rheum Dis       Date:  1978-08       Impact factor: 19.103

Review 8.  Anti-Ro(SSA) and anti-La(SSB) antibodies in autoimmune rheumatic diseases.

Authors:  P Youinou; Y Adler; S Muller; A Lamour; D Baron; R L Humbel
Journal:  Clin Rev Allergy       Date:  1994

9.  Clinical significance of antibodies to ribonucleoprotein.

Authors:  M L Cohen; B Dawkins; R L Dawkins; E T Owen
Journal:  Ann Rheum Dis       Date:  1979-02       Impact factor: 19.103

10.  Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap.

Authors:  T Mimori; M Akizuki; H Yamagata; S Inada; S Yoshida; M Homma
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.